Literature DB >> 11278475

Factor VIIa modified in the 170 loop shows enhanced catalytic activity but does not change the zymogen-like property.

K Soejima1, J Mizuguchi, M Yuguchi, T Nakagaki, S Higashi, S Iwanaga.   

Abstract

Factor VIIa (VIIa) is an unusual trypsin-type serine proteinase that appears to exist in an equilibrium between minor active and dominant zymogen-like inactive conformational states. The binding of tissue factor to VIIa is assumed to shift the equilibrium into the active state. The proteinase domain of VIIa contains a unique structure: a loop formed by a disulfide bond between Cys310 and Cys329, which is five residues longer than those of other trypsin types. To examine the functional role of the loop region, we prepared two mutants of VIIa. One of the mutants, named VII-11, had five extra corresponding residues 316-320 of VII deleted. The other mutant, VII-31, had all of the residues in its loop replaced with those of trypsin. Functional analysis of the two mutants showed that VIIa-11 (Kd = 41 nm) and VIIa-31 (Kd = 160 nm) had lower affinities for soluble tissue factor as compared with the wild-type VIIa (Kd = 11 nm). The magnitude of tissue factor-mediated acceleration of amidolytic activities of VIIa-11 (7-fold) and that of VIIa-31 (2-fold) were also smaller than that of wild-type VIIa (30-fold). In the absence of tissue factor, VIIa-31 but not VIIa-11 showed enhanced activity; the catalytic efficiencies of VIIa-31 toward various chromogenic substrates were 2-18-fold greater than those of the wild-type VIIa. Susceptibility of the alpha-amino group of Ile-153 of VIIa-31 to carbamylation was almost the same as that of wild-type VIIa, suggesting that VIIa-31 as well as wild-type VIIa exist predominantly in the zymogen-like state. Therefore, the tested modifications in the loop region had adverse effects on affinity for tissue factor, disturbed the tissue factor-induced conformational transition, and changed the catalytic efficiency of VIIa, but they did not affect the equilibrium between active and zymogen-like conformational states.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11278475     DOI: 10.1074/jbc.M009206200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity.

Authors:  E Persson; M Kjalke; O H Olsen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

2.  Molecular Basis of Enhanced Activity in Factor VIIa-Trypsin Variants Conveys Insights into Tissue Factor-mediated Allosteric Regulation of Factor VIIa Activity.

Authors:  Anders B Sorensen; Jesper J Madsen; L Anders Svensson; Anette A Pedersen; Henrik Østergaard; Michael T Overgaard; Ole H Olsen; Prafull S Gandhi
Journal:  J Biol Chem       Date:  2015-12-22       Impact factor: 5.157

3.  Design and Synthesis of Phenylpyrrolidine Phenylglycinamides As Highly Potent and Selective TF-FVIIa Inhibitors.

Authors:  Xiaojun Zhang; Wen Jiang; Swanee Jacutin-Porte; Peter W Glunz; Yan Zou; Xuhong Cheng; Alexandra H Nirschl; Nicholas R Wurtz; Joseph M Luettgen; Alan R Rendina; Gang Luo; Timothy M Harper; Anzhi Wei; Rushith Anumula; Daniel L Cheney; Robert M Knabb; Pancras C Wong; Ruth R Wexler; E Scott Priestley
Journal:  ACS Med Chem Lett       Date:  2013-12-26       Impact factor: 4.345

4.  Disulfide locked variants of factor VIIa with a restricted beta-strand conformation have enhanced enzymatic activity.

Authors:  Henry R Maun; Charles Eigenbrot; Helga Raab; David Arnott; Lilian Phu; Sherron Bullens; Robert A Lazarus
Journal:  Protein Sci       Date:  2005-05       Impact factor: 6.725

5.  Beating tissue factor at its own game: Design and properties of a soluble tissue factor-independent coagulation factor VIIa.

Authors:  Anders B Sorensen; Inga Tuneew; L Anders Svensson; Egon Persson; Henrik Østergaard; Michael Toft Overgaard; Ole H Olsen; Prafull S Gandhi
Journal:  J Biol Chem       Date:  2019-12-04       Impact factor: 5.157

6.  A frequent human coagulation Factor VII mutation (A294V, c152) in loop 140s affects the interaction with activators, tissue factor and substrates.

Authors:  Raffaella Toso; Mirko Pinotti; Katherine A High; Eleanor S Pollak; Francesco Bernardi
Journal:  Biochem J       Date:  2002-04-15       Impact factor: 3.857

7.  Allostery in Coagulation Factor VIIa Revealed by Ensemble Refinement of Crystallographic Structures.

Authors:  Anders B Sorensen; Jesper J Madsen; Thomas M Frimurer; Michael T Overgaard; Prafull S Gandhi; Egon Persson; Ole H Olsen
Journal:  Biophys J       Date:  2019-04-02       Impact factor: 4.033

8.  Augmented intrinsic activity of Factor VIIa by replacement of residues 305, 314, 337 and 374: evidence of two unique mutational mechanisms of activity enhancement.

Authors:  Egon Persson; Helle Bak; Anette Østergaard; Ole H Olsen
Journal:  Biochem J       Date:  2004-04-15       Impact factor: 3.857

9.  Mechanism of the Ca2+-induced enhancement of the intrinsic factor VIIa activity.

Authors:  Jais R Bjelke; Ole H Olsen; Michel Fodje; L Anders Svensson; Susanne Bang; Gert Bolt; Birthe B Kragelund; Egon Persson
Journal:  J Biol Chem       Date:  2008-07-17       Impact factor: 5.157

10.  Factor VII mutant V154G models a zymogen-like form of factor VIIa.

Authors:  Raffaella Toso; Francesco Bernardi; Theresa Tidd; Mirko Pinotti; Rodney M Camire; Giovanna Marchetti; Katherine A High; Eleanor S Pollak
Journal:  Biochem J       Date:  2003-02-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.